Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as JNJ-64417184 600 (Oral Tablet Formulation)
JNJ-64417184 600 · 1 trial · 1 indication
The relative bioavailability based on Cmax, AUC(0last), and AUC(0-infinity) will be estimated as 100\*Test/Reference where Test is tablet formulation of JNJ-64417184 and Reference is suspension formulation of JNJ-64417184 administered orally in a fasted state.
| Arm | Type | Description |
|---|---|---|
| Group 1: JNJ-64417184 | EXPERIMENTAL | Participants will receive JNJ-64417184 600 milligram (mg) oral tablet under fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg oral tablet in fed conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg as oral suspension in fasted condition on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period. |
| Group 2: JNJ-64417184 | EXPERIMENTAL | Participants will receive JNJ-64417184 600 mg oral tablet under fed conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period. |
| Group 3: JNJ-64417184 | EXPERIMENTAL | Participants will receive JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fed conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period. |
| Group 4: JNJ-64417184 | EXPERIMENTAL | Participants will receive JNJ-64417184 600 mg tablet under fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fed conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period. |
| Group 5: JNJ-64417184 | EXPERIMENTAL | Participants will receive JNJ-64417184 600 mg tablet under fed conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period. |
| Group 6: JNJ-64417184 | EXPERIMENTAL | Participants will receive JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg tablet under fed conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period. |
| Name | Type | Description |
|---|---|---|
| JNJ-64417184 600 (Oral Tablet Formulation) | DRUG | Participants will receive 600 mg of JNJ-64417184 as oral tablet. |
| JNJ-64417184 (Oral Suspension Formulation) | DRUG | Participants will also receive JNJ-64417184 600 mg as oral suspension. |
Inclusion Criteria: * Healthy on the basis of physical examination, medical and surgical history, and vital signs performed at screening. If there are abnormalities, the participant may be included only if the investigator judges the abnormalities to be not clinically significant or to be appropria...
JNJ-64417184 600 is an oral tablet formulation of JNJ-64417184, a small molecule therapeutic candidate developed by Johnson & Johnson. It has been studied in a Phase 1 clinical trial in healthy participants. The specific disease indications for this drug candidate have not been disclosed.
JNJ-64417184 600 is being developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker symbol JNJ. Johnson & Johnson is the sponsor of the clinical program for this oral tablet formulation.
JNJ-64417184 600 is in Phase 1 clinical development. It is an investigational drug candidate and has not been approved by the FDA. The Phase 1 program consists of one completed trial.
JNJ-64417184 600 has been evaluated in one Phase 1 clinical trial, NCT03952507, titled "A Study to Assess the Relative Oral Bioavailability and Food Effect of Single-dose of JNJ-64417184 in Healthy Participants." The trial was completed, enrolled 18 healthy volunteers, and was conducted in the United States.
JNJ-64417184 600 is an oral tablet formulation of JNJ-64417184. The two names refer to the same active drug candidate, with JNJ-64417184 600 specifying the oral tablet version studied in the Phase 1 trial.